Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICP-022 in R/R DLBCL
NCT04438005Phase 2Completed
- Sponsor
- InnoCare Pharma
- Start
- May 2020
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of orelabrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by InnoCare Pharma. Started May 2020; status: completed.
02
Drugs
orelabrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04438005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04438005.